Impact of myocardial contrast echocardiography on vascular permeability: an in vivo dose response study of delivery mode, pressure amplitude and contrast dose.
An in vivo rat model of myocardial contrast echocardiography (MCE) was defined and used to examine the dose range response of microvascular permeabilization and premature ventricular contractions (PVCs) with respect to method of imaging, peak rarefactional pressure amplitude (PRPA) and agent dose. A left ventricular short axis view was obtained on anesthetized rats at 1.7 MHz using a diagnostic ultrasound system with simultaneous ECG recording. Evans blue dye, a marker for microvascular leakage, and a bolus of Optison were injected i.v. Counts of PVCs were made from video tape during the 3 min of MCE. Hearts were excised 5 min after imaging and petechial hemorrhages, Evans blue colored area and Evans blue content were determined. No PVCs or microvascular leakage were seen in rats imaged without contrast agent followed by contrast agent injection without imaging. When PVCs were detected during MCE, petechial hemorrhages and Evans blue leakage were also found in the myocardium. Triggering 1:4 at end-systole produced the most PVCs per frame and most microvascular leakage, followed by end-systole 1:1, continuous scanning and end-diastole triggering 1:1. All effects increased with increasing Optison dosage in the range 25 to 500 microL kg(-1). Ultrasound PRPA was important, with apparent thresholds for PVCs at 1.0 MPa and for petechiae at 0.54 MPa. PVCs, petechial hemorrhages and microvascular leakage in the myocardium occur as a result of MCE in rats.
Li
Peng
P
Department of Cardiology, University of Michigan, Ann Arbor, MI 48109-0553, USA.
Cao
Lu-qin
LQ
Dou
Chun-Yan
CY
Armstrong
William F
WF
Miller
Douglas
D
D000418:Albumins / Q000008:administration & dosage / Q000633:toxicity*; D000818:Animals; D002199:Capillary Permeability / Q000187:drug effects*; D003287:Contrast Media / Q000008:administration & dosage / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D004452:Echocardiography / Q000009:adverse effects* / Q000379:methods; D005070:Evans Blue; D005466:Fluorocarbons / Q000008:administration & dosage / Q000633:toxicity*; D007275:Injections, Intravenous; D008863:Microspheres; D011693:Purpura / Q000139:chemically induced; D051381:Rats; D018879:Ventricular Premature Complexes / Q000139:chemically induced*
D000418:Albumins; D003287:Contrast Media; C099458:FS 069; D005466:Fluorocarbons; D005070:Evans Blue